INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 46m ago
HOUSE PTR6m ago
SEC 13F6m ago
ROBINHOOD CHAIN6m ago
SEC FORM 4/Tax withholdingVerified data

Grimaud Brett A. reported TBPH

SVP, GEN COUNSEL AND SECRETARY · Theravance Biopharma, Inc. · Ordinary Shares

Side
F
Value
$410K
Shares
20.8K
Price
$19.66
Executed
Feb 20, 2026
Disclosed
Feb 24, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Feb 20 executedFeb 24, 2026 disclosed

TBPH · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
19/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Tax withholding — administrative, little informational value

  • Relative size+11 / 25

$410K reported value · 6.6% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TBPH

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    2
    FR
    Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    150.0K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MA
    Miller AineSVP, DEV & HEAD OF IRE OFFICE
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    96.7K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MA
    Miller AineSVP, DEV & HEAD OF IRE OFFICE
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    37.5K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GA
    Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    223.9K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GA
    Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    107.8K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SA
    Sawaf AzizSVP & CHIEF FINANCIAL OFFICER
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    108.4K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SA
    Sawaf AzizSVP & CHIEF FINANCIAL OFFICER
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    23.4K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    2
    FR
    Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    124.4K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    2
    FR
    Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    89.1K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    6,009 sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    42.1K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    32.7K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    22.0K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    23.6K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    21
    MA
    Miller AineSVP, DEV & HEAD OF IRE OFFICE
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    93.1K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    13.4K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    24.3K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GA
    Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    23.4K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SA
    Sawaf AzizSVP & CHIEF FINANCIAL OFFICER
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    205.0K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    1
    FR
    Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
    TBPHTheravance Biopharma, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$113K
    6,657 sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001966698-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 20, 2026
    Published
    Feb 24, 2026
    Ingested by INSIDER
    Nov 5, 04:15 UTC
    Last re-read
    Nov 5, 04:15 UTC

    Extracted facts

    Filer
    Grimaud Brett A.
    Role
    SVP, GEN COUNSEL AND SECRETARY
    Transaction
    Tax withholdingAs filed: “F”
    Asset
    Theravance Biopharma, Inc.
    Ticker
    TBPH
    Shares
    20.8K
    Price per share
    $19.66
    Value
    $409,577
    Execution date (reported)
    Feb 20, 2026
    Owned after transaction
    334.4K shares
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 20.8K
    • Price: $19.66

    = $409,577

    What this establishes

    Grimaud Brett A. filed this Form 4 reporting a tax withholding of TBPH on Feb 20, 2026. It became public on Feb 24, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP, GEN COUNSEL AND SECRETARY
    Grimaud Brett A.cik:0001966698
    Issuer
    Theravance Biopharma, Inc.cik:0001583107

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.